Enapotamab vedotin is an investigational antibody-drug conjugate (ADC) specifically targeting the receptor tyrosine kinase AXL. it consists of a monoclonal antibody linked to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) and demonstrates significant inhibitory potential against high AXL-expressing non-small cell lung cancer (NSCLC), including tumors with resistance to EGFR inhibitors like Osimertinib.

Enapotamab vedotin (0-10 μg/mL, 5 days) treatment of AXL-overexpressing cells (ER20 and H1975-OR2) can reduce cell viability and produce cytotoxic effects. [1]

Methods: Enapotamab vedotin (2-4 mg/kg, intravenous injection, twice weekly) was used to treat LU1868 or LU0858 xenograft mouse models or AXL-overexpressing non-small cell lung cancer (NSCLC) models (e.g., LU0395) to observe its anti-tumor effects. Results: Enapotamab vedotin showed anti-tumor efficacy against AXL-overexpressing non-small cell lung cancer (NSCLC) models (e.g., LU0395) and showed resistance to EGFR inhibitors in LU1868 or LU0858 xenograft mouse models [1].